NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pathos

Pathos

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://www.pathos.com/

Last Round

Series D

May 15, 2025

Est. Valuation

$1.6B

Total Funding Raised

$467M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pathos is a clinical-stage biotechnology company that utilizes an AI-enabled drug discovery platform to accelerate the development of precision oncology therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Foundation

Keywords

oncology drug discoveryAI-driven drug discoveryclinical trial designAI drug discoverybiotech AItech-enabled biotechfoundation modelmultimodal datain-licensingdrug developmentclinical-stage biotechfrontier AI labdata as a serviceDaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pathos Comparables

Compare Pathos with similar companies based on industry and business-model similarity.

Pathos comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Insitro
84%
Zephyr AI
84%
Owkin
81%

Pathos Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DMay 15, 2025
Series COct 29, 2024
Series BMar 2, 2023
Series AJul 1, 2021

Key People

Founding team and executive leadership

Iker Huerga

Chief Executive Officer

Executive Team

Matthew De Silva

Chief Operating Officer

Executive Team

Pathos Investors

Notable investors and investment history

Pathos investors
InvestorRounds
Builders VCSeries C, Series B, Series A
LightbankSeries C, Series B, Series A
New Enterprise Associates (NEA)Series B, Series A, Series C
Revolution VenturesSeries C
Revolution GrowthSeries C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    AI drug development platform Foundry is now live and in production.

  • Jan 10, 2026

    Oncology drug programs in Phase 1/2 clinical trials with FDA IND applications.

Pathos Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pathos Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pathos's valuation, stock price, and market status.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range101
Year Founded2022
Last FundingMay 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.